Drug Profile
ACE 1334
Alternative Names: ACE-1334; MK-2225Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Class Antifibrotics; Immunoglobulin Fc fragments; Proteins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Systemic scleroderma
- No development reported Lung disorders
Most Recent Events
- 18 Oct 2023 Acceleron Pharma terminates phase I/II trial in Systemic sclerosis in the USA, Italy, Canada and Switzerland (SC) due to business reasons (NCT04948554)
- 10 Mar 2023 Phase-I clinical trials in Systemic scleroderma (In the elderly, In adults) in Switzerland (SC), Canada (SC), Italy (SC) (NCT04948554)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Lung-disorders(In volunteers) in USA (SC)